For instance, mAbs targeting Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) have dramatically improved the survival outcomes of patients affected by lung cancer, breast cancer and other solid malignancies [8,9]. Here, ERBB2 is linked to breast carcinoma.